Completed PHASE1 INTERVENTIONAL 2-arm NCT00923533

A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers

An Open-label, Multiple-dosing, Crossover, and Parallel Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers

Sponsor: Boryung Pharmaceutical Co., Ltd

Conditions Essential Hypertension

Interventions Fimasartan Hydrochlorothiazide

Updated 5 times since 2017 Last updated: Oct 7, 2009 Started: Mar 31, 2009 Primary completion: May 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Essential Hypertension, this trial is completed. The trial is conducted by Boryung Pharmaceutical Co., Ltd and has accumulated 5 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boryung Pharmaceutical Co., Ltd

Data source: Boryung Pharmaceutical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.